Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals-Reference-Cited by-同舟云学术

Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals

Published:2022-02-18 Issue:2 Volume:5 Page:e220045
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Li Yufei¹²³,Xu Susan¹⁴

Affiliation:

1. Association of American Medical Colleges, Washington, DC

2. Partnered Evidence-based Policy Resource Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts

3. Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts

4. McDermott + Consulting, Washington, DC

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2789170/li_2022_oi_220002_1657552980.23971.pdf

Reference16 articles.

1. Differences in spending on provider-administered chemotherapy by site of care in Medicare.;Kalidindi;Am J Manag Care,2018

2. Hospital teaching status and mMedicare expenditures for complex surgery.;Pradarelli;Ann Surg,2017

3. Geographical variations in Medicare spending.;Shine;Ann Intern Med,2003

4. Understanding differences between high- and low-price hospitals: implications for efforts to rein in costs.;White;Health Aff (Millwood),2014

5. Hospital ownership and drug utilization under a global budget: a quantile regression analysis.;Zhang;Int Health,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing provider knowledge of the federal 340B Drug Pricing Program in a federally qualified health center;American Journal of Health-System Pharmacy;2024-04-01

2. Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer‐Reviewed Literature;The Milbank Quarterly;2024-01-28

3. Financial Incentives In Biosimilar Uptake;Health Affairs;2023-09-01

4. Comparison of Generic Prescribing Patterns Among 340B-Eligible and Non-340B Prescribers in the Medicare Part D Program;JAMA Health Forum;2023-05-19

5. Errors in Methods;JAMA Network Open;2022-07-12